康莱特联合氟尿嘧啶腹腔化疗治疗晚期胃癌  

Kanglaite combined with fluorouracil intraperitoneal chemotherapy in the treatment of advanced gastric cancer

作　　者：詹姗姗[1] 王志刚[1] 傅木昌[1] 

机构地区：[1]人民解放军第161中心医院肿瘤科,湖北武汉430010

出　　处：《现代肿瘤医学》2009年第1期87-89,共3页Journal of Modern Oncology

摘　　要：目的:观察康莱特联合氟尿嘧啶腹腔化疗治疗晚期胃癌的临床疗效及副作用。方法:康莱特200ml,静滴,d1-21,氟尿嘧啶1.0g,腹腔灌注,d1,8,15,28天为一周期,共2-6周期,2周期后评价疗效。结果:33例患者总有效率为27.27%(9/33),疾病控制率为66.67%(22/33),中位疾病进展时间为4.1月,临床受益反应评价有效者占78.79%(26/33)。结论:康莱特联合氟尿嘧啶腹腔化疗治疗晚期胃癌疗效好,毒性低。Objective：To evaluate the clinical efficacy and toxicity of kanglaite combined with fiuorouracil perito- neal perfusion in the treatment of advanced gastric cancer （ AGC ）. Methods： Thirty three patients were treated with kanglaite （200ml,iv, dl - 21 ） and fluorouracil （ 1.0g, peritoneal perfusion, dl, 8,15 ） , repeated every 4 weeks for 2 -6 cycles. The efficacy was evaluated after 2 cycles. Results：The total response rate （RR） was 27.27% （9/33）. Disease control rate （DCR） was 66.67% （22/33）. Median time to progression （mTTP） was 4.1 months. The clinical beneficial response （CBR） was 78.79% （26/33）. Conclusion： Kanglaite combined with fluorouracil peritoneal perfusion in the treatment of advanced gastric cancer is effective and tolerable.

关 键 词：康莱特 氟尿嘧啶 晚期胃癌 腹腔化疗 

分 类 号：R735.2[医药卫生—肿瘤]